Journal article
From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation
Pharmacogenomics, Vol.19(10), pp.861-871
06/19/2018
DOI: 10.2217/pgs-2018-0023
PMCID: PMC6219447
PMID: 29914292
Abstract
Smoking cessation treatment outcomes may be heavily influenced by genetic variations among smokers. Therefore, identifying specific variants that affect response to different pharmacotherapies is of major interest to the field. In the current study, we systematically review all studies published in or after the year 1990 which examined one or more gene–drug interactions for smoking cessation treatment. Out of 644 citations, 46 articles met the inclusion criteria for the systematic review. We summarize evidence on several genetic polymorphisms (
CHRNA5-A3-B4, CYP2A6, DBH, CHRNA4, COMT, DRD2, DRD4 and CYP2B6
) and their potential moderating pharamacotherarpy effects on patient cessation efficacy rates. These findings are promising and call for further research to demonstrate the effectiveness of genetic testing in personalizing treatment decision-making and improving outcome.
Details
- Title: Subtitle
- From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation
- Creators
- Naji C Salloum - Washington University in St. LouisErica LF Buchalter - Washington University in St. LouisSwati Chanani - Washington University in St. LouisGemma Espejo - Washington University in St. LouisMahjabeen S Ismail - Washington University in St. LouisRandy O Laine - Washington University in St. LouisMaysaa Nageeb - Washington University in St. LouisA Benjamin Srivastava - Washington University in St. LouisNicholas Trapp - Washington University in St. LouisLudwig Trillo - Washington University in St. LouisErica Vance - Washington University in St. LouisMichael Wenzinger - Washington University in St. LouisSarah M Hartz - Washington University in St. LouisSean P David - Stanford UniversityLi-Shiun Chen - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- Pharmacogenomics, Vol.19(10), pp.861-871
- DOI
- 10.2217/pgs-2018-0023
- PMID
- 29914292
- PMCID
- PMC6219447
- NLM abbreviation
- Pharmacogenomics
- ISSN
- 1462-2416
- eISSN
- 1744-8042
- Publisher
- Future Medicine Ltd
- Alternative title
- Salloum, Buchalter, Chanani et al
- Language
- English
- Date published
- 06/19/2018
- Academic Unit
- Psychiatry; Iowa Neuroscience Institute
- Record Identifier
- 9984281751802771
Metrics
19 Record Views